ENO1 Enzyme Emerges as Target in Prostate Cancer
Laboratory research reports that the enzyme ENO1 is more abundant than ENO2 in several metastatic and neuroendocrine prostate cancer cell types.
Updated on Nov. 18, 2026 in Cancer

Researchers reported in a study published October 29, 2026, in the International Journal of Molecular Sciences that ENO1 is more abundant than ENO2 on PSMA-negative metastatic castration-resistant and neuroendocrine prostate cancer cells. Silencing ENO1 reduced cell proliferation and clonogenic growth even when ENO2 was upregulated.
Why it matters
The findings identify ENO1 as a potential therapeutic target in prostate cancer subtypes that do not express PSMA, a marker used for some existing treatments. Targeting cell surface ENO1 with a monoclonal antibody reduced growth of docetaxel-resistant cells in laboratory models.
The evidence comes from laboratory cell-culture experiments and transcript analysis of clinical prostate tumors, showing ENO1 transcript expression significantly higher than ENO2 across tumor grades including neuroendocrine tumors. Whether an ENO1-targeting antibody would produce similar effects in patients has not been tested in the reported work.
The players
International Journal of Molecular Sciences
An open-access, peer-reviewed scientific journal published by MDPI that covers molecular biology and biochemistry.
UroToday
An online urology education and news platform that publishes summaries of urology and oncology research.
The details
Researchers silenced ENO1 in prostate cancer cells and found reduced proliferation and clonogenic growth even when ENO2 was upregulated. A monoclonal antibody targeting cell surface ENO1 decreased proliferation, clonogenicity and tumorsphere formation in metastatic castration-resistant cells, including docetaxel-resistant cells, and was associated with increased apoptosis.
Timeline
October 29, 2026: Study published in the International Journal of Molecular Sciences.
November 18, 2026: Abstract published on UroToday.
Treatment Landscape
The research extends the search for targeted therapies beyond PSMA, the target of established radioligand treatments, to PSMA-negative metastatic and neuroendocrine prostate cancers that lack that marker. The results remain at the preclinical and tumor-transcript stage.
For patients with PSMA-negative prostate cancer, the findings point to a possible future treatment target but do not change current care. Any therapy based on ENO1 would require clinical trials before it could be available.
The takeaway
Scientists are continuing to look beyond the best-known prostate cancer markers to find targets for cancers that do not express them. Readers should watch for clinical studies before drawing conclusions about treatment applications.
Further reading
For broader background on treatment research, explore the Cancer section.
Source note: This article includes information reported by Urotoday.






